Due to the lack of targetable receptors, estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2), treatment options for TNBC are limited [2]. Liver metastasis has been reported as the initial site of recurrence in approximately 13.7% of TNBC cases [3]. While hepatic metastases from breast cancer are typically regarded as a manifestation of systemic disease with a poor outlook, radiofrequency ablation (RFA) has shown promise as a safe treatment option in selected patients, potentially contributing to prolonged survival [4,5]. This evidence concerns the gene ERBB2 and breast cancer.